Self-microemulsifying drug-delivery system for improved oral bioavailability of probucol: Preparation and evaluation

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 705-712

  Sha, Xianyi ^a   Wu, Juan ^a   Chen, Yanzuo ^a   Fang, Xiaoling ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Bioavailability; Probucol; Self microemulsifying drug delivery system (SMEDDS)

Indexed keywords

PROBUCOL; DRUG CARRIER; LIPID;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; NONHUMAN; RAT; SUSPENSION; ANIMAL; CHEMISTRY; EMULSION; PARTICLE SIZE; SOLUBILITY; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; DRUG CARRIERS; EMULSIONS; LIPIDS; MALE; PARTICLE SIZE; PROBUCOL; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 84862326451     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S28052     Document Type: Article

References (27)

1. Heel RC, Brogden RN, Speight TM, Avery GS. Probucol: a review of its pharmacological properties and therapeutic use in patients with hypercholesterolemia. Drugs. 1978;15:409-428.
2. Li GP, Yin L, Liu T, et al. Role of probucol in preventing contrastinduced acute kidney injury after coronary interventional procedure. Am J Cardiol. 2009;103:512-514.
3. Sawayama Y, Shimizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol. 2002;39:610-616.
4. Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: Linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci. 2005;26:394-404.
5. Physicians' desk reference: Lorelco Tablets. 1995;49:1408-1410.
6. Pouton CW, Porter JH. Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Adv Drug Deliv Rev. 2008;60:625-637.
7. Sagar DM, Shobhona S, Sulabha P, Vandana BP. Development of SMEDDS using natural lipophile: application to S-artemether delivery. Int J Pharm. 2008;362:179-183.
8. Mette G, Anette M, Jeanet LN, Gitte PP. Bioavailability of seocalcitol II: Development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. Eur J Pharm Sci. 2006;28:233-242.
9. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci. 2000;11:93-98.
10. Holt DW, Johnston A. Which cyclosporin formulation? Lancet. 1996;348: 1175.
11. Patel AR, Vavia PR. Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate. AAPS J. 2007;9:344-352.
12. Qi XD, Cao DY. Preparation and in vivo evaluation of probucol solid dispersion. Chinese Journal of Pharmaceuticals. 2005;36:483-486.
13. Henar O, José LC, Patricia C. Liquid chromatographic method for the simultaneous determination of different lipid-soluble antioxidants in human plasma and low-density lipoproteins. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;803:249-255.
14. Gershanik T, Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm. 2000;50:179-188.
15. Nielsen FS, Petersen KB, Mullertz A. Bioavailability of probucol from lipid and surfactant based formulations in minipigs: Influence of droplet size and dietary state. Eur J Pharm Biopharm. 2008;69:553-562.
16. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6:231-248.
17. Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev. 1997;25:47-58.
18. Humberstone AJ, Charman WN. Lipid based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev. 1997;25: 103-128.
19. Palin KJ, Wilson CJ. The effect of different oils on the absorption of probucol in the rat. J Pharm Pharmacol. 1984;36:641-643.
20. Yamamoto K, Fukuda N, Shiroi S, et al. Effects of dietary fat levels on the absorption and tissue accumulation of probucol in the rat. Arzneimittelforschung. 1994;44:1059-1062.
21. Brian K, Nordskoga CT, Phana DF. An examination of the factors affecting intestinal lymphatic transport of dietary lipids. Adv Drug Deliv Rev. 2001;50:21-44.
22. Fergal S. Stimulation of triglyceride-rich lipoprotein secretion by polysorbate 80: in vitro and in vivo correlation using Caco-2 cells and a cannulated rat intestinal lymphatic model. Pharm Res. 2004; 21:2320-2326.
23. Hernell O, Staggers JE, Carey MC. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase behaviour and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. Biochemistry. 1990;29:2041-2056.
24. Staggers JE, Hernell O, Stafford RJ, Carey MC. Physical-chemical behaviour of dietary and biliary lipids during intestinal digestion and absorption. 1. Phase behaviour and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings. Biochemistry. 1990;29:2028-2040.
25. Skagerlind P, Jansson M, Hult K. Surfactant interference on lipase catalysed reactions in microemulsions. J Chem Technol Biotechnol. 1992;54:277-282.
26. Canioni P, Julien R, Rathelot J, Sarda L. Inhibition of sheep pancreatic lipase activity against emulsified tributyrin by non-ionic detergents. Biochimie. 1976;58:751-753.
27. Reis P, Holmberg K, Watzke H, Leser ME, Miller R. Lipases at interfaces: A review. Adv Coll Interface Sci. 2009:147-148, 237-250.